| 0.2071 0.011 (5.66%) | 10-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.2 | 1-year : | 0.23 |
| Resists | First : | 0.17 | Second : | 0.19 |
| Pivot price | 0.14  |
|||
| Supports | First : | 0.13 | Second : | 0.1 |
| MAs | MA(5) : | 0.13 |
MA(20) : | 0.14 |
| MA(100) : | 0.24 |
MA(250) : | 0.45 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.2 |
D(3) : | 15.4 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 2.4 | Low : | 0.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RNLX ] has closed above bottom band by 29.5%. Bollinger Bands are 63.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.16 - 0.16 | 0.16 - 0.16 |
| Low: | 0.14 - 0.14 | 0.14 - 0.14 |
| Close: | 0.14 - 0.14 | 0.14 - 0.14 |
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.
Thu, 15 Feb 2024
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024 - GlobeNewswire
Wed, 10 Jan 2024
New published data demonstrates KidneyIntelX™ has broad implications for winning war on chronic kidney disease - Yahoo Finance
Sat, 23 Apr 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renalytix Plc - RNLX - PR Newswire
Wed, 30 Mar 2022
Renalytix Appoints Timothy Scannell to Board - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 83 (M) |
| Shares Float | 115 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 379 (K) |
| Shares Short P.Month | 183 (K) |
| EPS | -0.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.06 |
| Profit Margin | 0 % |
| Operating Margin | -942.9 % |
| Return on Assets (ttm) | -93.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 13.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -0.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.23 |
| PEG Ratio | 0 |
| Price to Book value | -2.82 |
| Price to Sales | 5.09 |
| Price to Cash Flow | -0.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|